THE MEDIAN SURVIVAL TIME OF PANCREATIC CANCER PATIENTS IN MALAYSIA
DOI:
https://doi.org/10.37268/mjphm/vol.22/no.3/art.1705Keywords:
Median survival time, pancreatic cancer, Kapalan-Meier Malaysia, retrospective studyAbstract
Pancreatic cancer is an intractable disease, and its mortality rates are approximately identical to its incidence ones. Getting its early diagnosis is quite challenging and subsequently, it contributes to one of the reasons for poor survival figures. The retrospective record review of radiologically or histo-pathologically confirmed primary pancreatic cancer cases registered at State hospitals in Penang, Kedah, Kelantan and Terengganu from 1st January 2011 to 31st December 2018 were performed. The cumulative survival probabilities were estimated using the Kaplan-Meier method while the log-rank test was applied to determine the differences in overall survival among groups. The overall median survival time was 9.37 (95% CI:8.53, 10.21) months since the diagnosis. The median survival times were significantly shorter in those aged >60 years, in Chinese subjects, those with smoking or alcohol consumption history, patients with some comorbidities, those presented with some signs and symptoms at the time of diagnosis. Moreover, the median survival time was found to be different based on the type of the pancreatic malignancy and staging of the disease. It was also found that the survival time was significantly longer in those who underwent surgery, those who received radiotherapy or chemotherapy whereas it was significantly shorter in those who took best supportive treatment. The disparities of overall survival time were observed depending on their socio-demographic data and clinical features at the time of diagnosis. The results of this study may serve as a solid foundation to develop robust and meaningful prediction modelling for the prognosis of pancreatic cancer.
References
Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6(4):321-337. doi:10.1177/1756283X13478680
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;0:1-41. doi:10.3322/CAAC.21660
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Res. 2014;74(11):2913-2921. doi:10.1158/0008-5472.CAN-14-0155
Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. Rev World J Oncol. 2019;10(1):10-27. doi:10.14740/wjon1166
Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med. 2014;371(11):1039-1049. doi:10.1056/NEJMra1404198
Bellon E, Gebauer F, Tachezy M, Izbicki JR, Bockhorn M. Pancreatic cancer and liver metastases: state of the art. Updates Surg. 2016;68(3):247-251. doi:10.1007/s13304-016-0407-7
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Facts and Figures 2021. CA Cancer J Clin. 2021;71(1):7-33. doi:10.3322/caac.21654
The World Bank. The World Bank in Malaysia. https://www.worldbank.org/en/country/malaysia/overview#1. Published 2021 (accessed September 30, 2021).
World Health Organization (WHO). Malaysia (Source: Globocan 2020).; 2021. https://gco.iarc.fr/today/data/factsheets/populations/458-malaysia-fact-sheets.pdf (accessed February 9, 2021).
Azizah AM, Hashimah B, Nirmal K, et al. Malaysia National Cancer Registry Report (MNCR) 2012-2016.; 2019. https://drive.google.com/file/d/1BuPWrb05N2Jez6sEP8VM5r6JtJtlPN5W/view (accessed May 3, 2021).
Malwinder S, Wi WZ, Cimmeran K, Vce P, Austin TM. Prognostic factors for survival in pancreatic cancer patients from university malaya medical centre, Malaysia. 2018;21(1):6-13.
Shahrudin MD. Carcinoma of the pancreas: resection outcome at the University Hospital Kuala Lumpur. Int Surg. 1997;82(3):269-274. http://www.ncbi.nlm.nih.gov/pubmed/9372373. Accessed November 18, 2019.
Norsa’adah B, Nur-Zafira A, Knight A. Pancreatic Cancer in Universiti Sains Malaysia Hospital: A Retrospective Review of Years 2001-2008. Asian Pacific J Cancer Prev. 2012;13(6). doi:10.7314/APJCP.2012.13.6.2857
Edge SB, Compton CC. The American Joint Committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-1474. doi:10.1245/s10434-010-0985-4
Dupont W, Plummer W. Power and Sample Size Calculations: A Review and Computer Program. Control Clin Trials. 1990;11:116-128. https://biostat.app.vumc.org/wiki/Main/PowerSampleSize. Accessed August 12, 2021.
IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.
Raju RS, Coburn NG, Liu N, et al. A population-based study of the epidemiology of pancreatic cancer: A brief report. Curr Oncol. 2015;22(6):e478-e484. doi:10.3747/co.22.2653
Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, Feliu J. Management of pancreatic cancer in the elderly. World J Gastroenterol. 2016;22(2):764-775. doi:10.3748/wjg.v22.i2.764
Khan S, Sclabas G, Lombardo KR, et al. Pancreatoduodenectomy for ductal adenocarcinoma in the very elderly; is it safe and justified? J Gastrointest Surg. 2010;14(11):1826-1831. doi:10.1007/S11605-010-1294-8
Wheeler. Age Influences Likelihood of Pancreatic Cancer Treatment, but not Outcome. World J Oncol. 2014. doi:10.14740/wjon789w
Mcguigan A, Kelly P, Turkington RC, Jones C, Coleman HG, Mccain S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846-4861. doi:10.3748/wjg.v24.i43.4846
Önal Ö, Yılmaz SD, Eroğlu HN, Eroğlu İ, Koçer M. Survival analysis and factors affecting survival in patients with pancreatic cancer. Med Sci Discov. 2020;7(2):412-418. doi:10.36472/msd.v7i2.352
Brotherton L, Welton M, Robb SW. Racial disparities of pancreatic cancer in Georgia: a county‐wide comparison of incidence and mortality across the state, 2000–2011. Cancer Med. 2016;5(1):100. doi:10.1002/CAM4.552
Pelucchi C, Galeone C, Polesel J, et al. Smoking and body mass index and survival in pancreatic cancer patients. Pancreas. 2014;43(1):47-52. doi:10.1097/MPA.0B013E3182A7C74B
Alsamarrai A, Das SLM, Windsor JA, Petrov MS. Factors That Affect Risk for Pancreatic Disease in the General Population: A Systematic Review and Meta-analysis of Prospective Cohort Studies. Clin Gastroenterol Hepatol. 2014;12:1635-1644.e5. doi:10.1016/j.cgh.2014.01.038
Zhang S, Wang C, Huang H, et al. Effects of alcohol drinking and smoking on pancreatic ductal adenocarcinoma mortality: A retrospective cohort study consisting of 1783 patients. Sci Rep. 2017;7(1). doi:10.1038/s41598-017-08794-1
Gapstur SM, Jacobs EJ, Deka A, McCullough ML, Patel A V., Thun MJ. Association of alcohol intake with pancreatic cancer mortality in never smokers. Arch Intern Med. 2011;171(5):444-451. doi:10.1001/archinternmed.2010.536
Wang D, Wang Z, Zhang L, et al. Are risk factors associated with outcomes in pancreatic cancer ? PLoS One. 2012;7(7):e41984. doi:10.1371/journal.pone.0041984
Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64(7):2634-2638. doi:10.1158/0008-5472.CAN-03-3823
Hruban RH, Canto M, Goggins M, Schulick R, Klein AP. Update on Familial Pancreatic Cancer.; 2010. http://astor.som.jhmi.edu/BayesMendel/pancpro.html (accessed March 4, 2019).
Lu C, Xu C-F, Wan X-Y, Zhu H-T, Yu C-H, Li Y-M. Screening for pancreatic cancer in familial high-risk individuals: A systematic review. World J Gastroenterol. 2015;21(28):8678-8686. doi:10.3748/wjg.v21.i28.8678
Torphy RJ, Schulick RD. Screening of Patients at Risk for Familial Pancreatic Cancer: What Is Beneficial? Surg Clin North Am. 2018;98(1):25-35. doi:10.1016/J.SUC.2017.09.003
Li Y, Bian X, Wei S, He M, Yang Y. The relationship between pancreatic cancer and type 2 diabetes: Cause and consequence. Cancer Manag Res. 2019;11:8257-8268. doi:10.2147/CMAR.S211972
Salvatore T, Marfella R, Rizzo MR, Sasso FC. Pancreatic cancer and diabetes: A two-way relationship in the perspective of diabetologist. Int J Surg. 2015;21(S1):S72-S77. doi:10.1016/J.IJSU.2015.06.063
Stein KB, Snyder CF, Barone BB, et al. Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2010;55(7):1839. doi:10.1007/S10620-009-0944-8
Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005;2(1):48-53. doi:10.1038/NCPONC0062
Kang SP, Saif MW. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the “2010 ASCO Annual Meeting”. Chicago, IL, USA. June 4-8, 2010. JOP. 2010;11(4):334-335. http://www.ncbi.nlm.nih.gov/pubmed/20601806 (accessed December 11, 2019).
Kim TD, Oh HJ, Kim KH, et al. [Clinical characteristics of pancreatic cancer according to the presence of diabetes mellitus] - PubMed. Korean J Gastroenterol.2004;43(1):35-40. https://pubmed.ncbi.nlm.nih.gov/14745250/. (accessed November 7, 2021).
Mao Y, Tao M, Jia X, et al. Effect of Diabetes Mellitus on Survival in Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis OPEN. 2015. doi:10.1038/srep17102
Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1(2). doi:10.1136/ESMOOPEN-2016-000042
World Health Organization. Hepatitis C in Malaysia: From crisis to hope. https://www.who.int/malaysia/news/detail/28-07-2020-hepatitis-c-in-malaysia-from-crisis-to-hope. Published July 2020 (accessed November 10, 2021).
Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Björnsson E. Increased Risk for Malignant Neoplasms Among Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2011;9(2):168-174. doi:10.1016/J.CGH.2010.10.014
Huang J, Magnusson M, Törner A, Ye W, Duberg A-S. Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: a nationwide study in Sweden. Br J Cancer 2013 10911. 2013;109(11):2917-2923. doi:10.1038/bjc.2013.689
Schizas D, Peppas S, Giannopoulos S, et al. The Impact of Cirrhosis on Pancreatic Cancer Surgery: A Systematic Review and Meta-Analysis. World J Surg. 2021;45(2):562-570. doi:10.1007/S00268-020-05821-7
Herbst MC. Fact Sheet on Pancreatic Cancer.; 2018. https://www.cansa.org.za/files/2018/01/Fact-Sheet-on-Pancreatic-Cancer-NCR-2013-web-January-2018.pdf (accessed December 9, 2018).
Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med. 2014;371(11):1039-1049. doi:10.1056/NEJMRA1404198
Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in Survival by Histologic Type of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1766-1773. doi:10.1158/1055-9965.EPI-05-0120
American Society of Clinical Oncology (ASCO). Neuroendocrine Tumor of the Pancreas: Statistics. Cancer.Net. https://www.cancer.net/cancer-types/neuroendocrine-tumor-pancreas/statistics. Published February 2021 (accessed November 12, 2021).
Mustaf M, Menon J, Almohtafar B, Iiizam EM, Sharifa AM, Nang MK. Pancreatic Cancer : Diagnosis and Management. IOSR J Dent Med Sci. 2017;16(11):87-93. doi:10.9790/0853-1611018793
De La Cruz MSD, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89(8):626-632. http://www.ncbi.nlm.nih.gov/pubmed/24784121 (accessed March 9, 2019).
Robinson R. Early Identification of Pancreatic Cancer. Clin Rev. 2012;22(4):27-33.
